Climb Bio Earnings Call Transcripts
Fiscal Year 2026
-
The conference highlighted progress on two antibody programs for renal and autoimmune diseases, with upcoming data at ERA and ASN. Differentiation is driven by advanced technology, global partnerships, and a focus on dosing convenience and efficacy. Regulatory and scientific trends support further development.
-
Climb Bio presented updates on its two lead monoclonal antibody assets targeting serious renal and hematologic diseases, with multiple clinical data readouts expected in 2024. The company highlighted differentiation in safety, dosing, and market positioning, and is well-funded to advance pivotal studies.
-
Budoprutug is advancing in pMN, ITP, and SLE with robust early data, including durable remissions and strong B-cell depletion. Key 2026 data readouts will inform dose selection, clinical efficacy, and expansion plans, with subcutaneous formulation development enhancing market potential.
-
A year of foundational execution sets up multiple data readouts in 2026 for two lead antibody programs targeting B-cell mediated diseases. Key differentiators include broader B-cell targeting, subcutaneous formulations, and a novel APRIL-only antibody, with strong financial runway and ongoing business development focus.
-
The company is advancing two antibody assets, budoprutug (anti-CD19) and CLYM116 (anti-APRIL), targeting immune-mediated diseases with multiple clinical readouts expected this year. Budoprutug has shown durable remissions in PMN, while CLYM116 demonstrates superior preclinical efficacy in IgAN.
-
Multiple clinical readouts are expected in 2024 for two differentiated antibody programs targeting autoimmune diseases, with pivotal studies planned for PMN and IgAN. The company is well-funded into 2028 and is exploring further indication expansion for both assets.
Fiscal Year 2025
-
Multiple data readouts for two monoclonal antibodies are expected in 2026, targeting PMN, ITP, SLE, and IgA nephropathy. Dose optimization and subQ formulations are key strategies, with a strong financial runway through 2027.
-
Climb 116, a next-generation anti-APRIL sweeper antibody, is advancing toward clinical trials for IgA nephropathy, aiming for best-in-class efficacy with deeper and more durable IgA suppression and less frequent dosing. Preclinical data show superior PK/PD versus first-generation agents, and global development is supported by a partnership with Mabwell.
-
The company is advancing monoclonal antibody programs for B-cell mediated diseases, with Budoprutug and CLYM116 targeting CD19 and APRIL, respectively. Multiple clinical trials are underway, with a cash runway through 2027 and key data readouts expected in 2026 and later this year.
-
Focused on monoclonal antibodies for B-cell-mediated diseases, the company advances Budo (CD19-targeted) and CLYM116 (anti-APRO) with a data-driven, indication-bucketed strategy. Early clinical data show strong efficacy in PMN, with multiple studies ongoing and key data readouts expected in the next 12–18 months.
-
The company is advancing two main assets for immune-mediated diseases, focusing on CD19-targeted and anti-APRIL monoclonal antibodies. Early clinical data show strong efficacy and safety, with biomarker-driven strategies guiding development. Key priorities include execution, differentiation, and strategic indication selection.
-
Focused on immune-mediated diseases, the company is advancing two B-cell-targeting assets—Budo (CD19 MAB) and CLYM116 (APRIL sweeper MAB)—with strong early clinical data in PMN and upcoming studies in ITP and SLE. Well-funded through 2027, key 2024 milestones include multiple trial initiations and preclinical data updates.
-
The company is advancing two key monoclonal antibody assets for immune-mediated diseases, with Budo showing strong early efficacy in PMN and plans for further studies in ITP and SLE. CLYM116, a differentiated anti-APRIL antibody, is moving toward clinical trials. Both assets are supported by robust financial resources and strategic IP protection.
-
Focused on immune-mediated diseases, the company advances two antibody programs targeting B-cell and plasma cell pathways. Early clinical data show strong efficacy and safety, with multiple trials and key data readouts expected through 2025.
-
The company is advancing a pipeline of immune-mediated disease therapies, led by Budo, a potent CD19 antibody targeting PMN, ITP, and SLE, with early data showing strong efficacy and safety. CLYM116, an APRIL-targeted antibody for IgA nephropathy, is also progressing, with key data and clinical milestones expected this year.